

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptau129pxo

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 05:01:13 ON 22 MAR 2004

FILE 'STNGUIDE' ENTERED AT 05:01:32 ON 22 MAR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Mar 19, 2004 (20040319/UP).

FILE 'HOME' ENTERED AT 05:01:36 ON 22 MAR 2004

FILE 'REGISTRY' ENTERED AT 05:01:43 ON 22 MAR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAR 2004 HIGHEST RN 665776-10-3  
DICTIONARY FILE UPDATES: 19 MAR 2004 HIGHEST RN 665776-10-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting Smart SELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>  
Uploading C:\STNEXP4\QUERIES\759.str

L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR



G1 H, Ak  
G2 O, N, C

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 05:08:10 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 8056 TO ITERATE

12.4% PROCESSED 1000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 155742 TO 166498  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search 11  
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full

FULL SEARCH INITIATED 05:08:18 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 161324 TO ITERATE

100.0% PROCESSED 161324 ITERATIONS  
SEARCH TIME: 00.00.11

21 ANSWERS

L3 21 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
159.62	160.10

FILE 'CAPLUS' ENTERED AT 05:08:34 ON 22 MAR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Mar 2004 VOL 140 ISS 13  
FILE LAST UPDATED: 21 Mar 2004 (20040321/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
L4 10 L3

=> d 14 fbib ab hitstr 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:960938 CAPLUS  
DN 138:337781  
TI Efficient synthesis of a new potential chelating agent for radioimmunotherapy  
AU Gouin, Sebastien G.; Gestin, Jean-Francois; Remaud, Patricia; Faivre-Chauvet, Alain; Meslin, Jean Claude; Deniaud, David  
CS Laboratoire de Synthese Organique, UMR CNRS 6513, Faculte des Sciences et des Techniques, Nantes, 44072, Fr.  
SO Synlett (2002), (12), 2080-2082  
CODEN: SYNLES; ISSN: 0936-5214  
PB Georg Thieme Verlag  
DT Journal  
LA English  
OS CASREACT 138:337781  
AB The synthesis of a new rigid analog of cyclohexyl-TTHA, an efficient lanthanide ligand, as well as the first complexation trials are reported. This polyaminopolycarboxylic acid (I) was obtained in five steps from

o-phenylenediamine as starting product. The key intermediate was tetramine II, which after alkylation and hydrolysis gave I with ten coordination centers.


IT 518038-50-1P 518038-51-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of polyaminopolycarboxylic acid and its complexation with yttrium)


RN 518038-50-1 CAPLUS

CN Carbamic acid, [1,2-phenylenebis[imino(2-oxo-2,1-ethanediyl)]]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 518038-51-2 CAPLUS

CN Carbamic acid, [1,2-phenylenebis[imino(2-oxo-2,1-ethanediyl)]]bis-, bis(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:462923 CAPLUS

DN 137:241208

TI Introduction of Lanthanide(III) Chelates to Oligopeptides on Solid Phase

AU Peuralahti, Jari; Hakala, Harri; Mukkala, Veli-Matti; Loman, Kristiina; Hurskainen, Pertti; Mulari, Outi; Hovinen, Jari

CS PerkinElmer Life Sciences Wallac Oy, Turku, FIN-20101, Finland

SO Bioconjugate Chemistry (2002), 13(4), 870-875

CODEN: BCCHE; ISSN: 1043-1802

PB American Chemical Society

DT Journal

LA English

OS CASREACT 137:241208

AB The synthesis of oligopeptide building blocks for the introduction of nonluminescent and luminescent lanthanide(III) chelates to the oligopeptide structure on the solid phase is described. The oligopeptide conjugates synthesized were used in DELFIA-based receptor binding assay (motilin) as well as in LANCE time-resolved fluorescence quenching assay (caspase-3).

IT **450374-57-9P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nonluminescent and luminescent lanthanide(III) chelates and their incorporation in solid-phase peptide synthesis)


RN 450374-57-9 CAPLUS

CN 3-Oxa-6,9,12-triazatetradecan-14-oic acid, 6,9-bis[2-(1,1-dimethylethoxy)-2-oxoethyl]-12-[[4-[[[[9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]methyl]-2,2-dimethyl-4-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:149241 CAPLUS  
DN 136:340985  
TI A Noncovalent Approach to Antiparallel  $\beta$ -Sheet Formation  
AU Zeng, Huaqiang; Yang, Xiaowu; Flowers, Robert A. ,II; Gong, Bing  
CS Department of Chemistry, Natural Sciences Complex, State University of New York, Buffalo, NY, 14260, USA  
SO Journal of the American Chemical Society (2002), 124(12), 2903-2910  
CODEN: JACSAT; ISSN: 0002-7863  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 136:340985  
AB Four tripeptide chains, when attached to the same end of a hydrogen-bonded duplex peptides I·II (R = Me, iso-Bu; Ia has R = Me; Ib has R = iso-Bu; IIa has R = iso-Bu; IIb has R = Me) with the unsym., complementary sequences of ADAA/DADD, have been brought into proximity, leading to the formation of four hybrid duplexes, Ia·IIa, Ia·IIb, Ib·IIa, and Ib·IIb, each of which contains a two-stranded  $\beta$ -sheet segment. The extended conformations of the peptide chains were confirmed by 1D and 2D NMR. The peptide strands stay registered through hydrogen bonding and the  $\beta$ -sheets are stabilized by side chain interactions. Two-dimensional NMR data also indicate that the duplex template prevents further aggregation in the peptide segment. When the peptide chains are attached to the two different termini of the duplex template, NMR studies show the presence of a mixture with no clearly defined conformations. In the absence of the duplex template, the tripeptides are found to associate randomly. Finally, isothermal titration calorimetry studies revealed that the hybrid duplex Ia·IIa was more stable than either the duplex template or the peptides alone.  
IT 416899-51-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of hydrogen-bonded duplex templates with peptide chains that form antiparallel  $\beta$ -sheet-like structures)  
RN 416899-51-9 CAPLUS  
CN Benzoic acid, 3-[[[2-(octyloxy)-5-[(1-oxohexyl)amino]benzoyl]amino]acetyl]amino]-5-[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-, octyl ester (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2000:553906 CAPLUS  
 DN 133:335443  
 TI Synthesis of model compounds for potential contrast agents containing phosphonate and peptide moieties  
 AU Shalem, Hutt; Shatzmiller, Shimon; Feit, Ben-Ami  
 CS School of Chemistry, The Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv-Jaffa, 69978, Israel  
 SO Perkin 1 (2000), (16), 2831-2837  
 CODEN: PERKF9  
 PB Royal Society of Chemistry  
 DT Journal  
 LA English  
 OS CASREACT 133:335443  
 AB The synthesis of di-Me 2-acetoxy-2-(2,4-diiodo-5-aminophenyl)ethylphosphonate (I) and di-Me 2-acetoxy-2-(2,4,6-triiodo-3,5-diaminophenyl)ethylphosphonate (II) is described. Several amido derivs. III [X = CO(CH<sub>2</sub>)<sub>n</sub>CO; n = 0, 2, 4, 6] and peptide derivs. IV (R = Boc-Ala-Ala-, Cbz-Gly-Gly-, Cbz-Leu-Gly-, Cbz-Gly-Ala-, Cbz-Ala-Val-) of these phosphonates were prepared. These products are composed of a combination of structural/functional moieties which enable them to be potential nonionic, selective x-ray contrast agents.  
 IT 303183-55-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of phosphonates and their peptide derivs. as potential nonionic, selective x-ray contrast agents)  
 RN 303183-55-3 CAPLUS  
 CN Carbamic acid, [[5-[1-(acetoxy)-2-(dimethoxyphosphinyl)ethyl]-4,6-diiodo-1,3-phenylene]bis[imino(2-oxo-2,1-ethanediyl)]bis-, bis(phenylmethyl)ester (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2000:535988 CAPLUS  
 DN 133:267133  
 TI New highly potent dipeptidic growth hormone secretagogues with low molecular weight  
 AU Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Hansen, Birgit Sehested; Lau, Jesper; Nielsen, Karin Kramer; Raun, Kirsten  
 CS Health Care Chemistry, Novo Nordisk A/S, Malov, 2760, Den.  
 SO European Journal of Medicinal Chemistry (2000), 35(6), 599-618  
 CODEN: EJMCA5; ISSN: 0223-5234  
 PB Editions Scientifiques et Medicinales Elsevier  
 DT Journal

LA English  
 AB Based on NN703, low mol. weight growth hormone secretagogues (GHSS) with a reduced number of hydrogen binding sites were designed by removal of the C-terminal amide group. The compds. were highly potent in combination with high efficacy in a rat pituitary cell assay, being characterized with EC50 values down to 0.8 nM. Selected compds. were tested in in vivo animal models. The oral bioavailability in dogs was 16-44%. Also, the ED50 values of the compds. were determined both in dog and swine.  
 IT 202811-34-5P 202811-36-7P 202811-38-9P  
 297175-37-2P 297175-40-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and biol. activity of highly potent dipeptidic growth hormone secretagogues with low mol. wts.)  
 RN 202811-34-5 CAPLUS  
 CN Carbamic acid, [2-[2-[2-[2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 202811-36-7 CAPLUS  
 CN Carbamic acid, [(1R)-2-[2-[2-[2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202811-38-9 CAPLUS


CN Carbamic acid, [(3E)-5-[[[(1R)-2-[[2-[2-[[[[9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methylamino]-1,1-dimethyl-5-oxo-3-pentenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A





RN 297175-37-2 CAPLUS


CN Carbamic acid, [2-[[2-[(2-(methylamino)ethyl)phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 297175-40-7 CAPLUS

CN Carbamic acid, [2-[[2-[(2R)-2-[(methylamino)-3-(2-naphthalenyl)-1-oxopropyl]amino]ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1999:233909 CAPLUS  
DN 130:275757  
TI Contrasting agent for infarct and necrosis imaging of heart and kidneys  
IN Platzek, Johannes; Niedballa, Ulrich; Raduchel, Bernd; Ebert, Wolfgang;  
Weinmann, Hanns-Joachim  
PA Schering A.-G., Germany  
SO PCT Int. Appl., 112 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9916757	A1	19990408	WO 1998-EP5184	19980817
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
DE 19744003	A1	19990715	DE 1997-19744003A	19970926
CA 2304458	AA	19990408	DE 1997-19744003 19970926	19980817
AU 9893428	A1	19990423	CA 1998-2304458 19980817	19970926
EP 1017684	A1	20000712	DE 1997-19744003A 19970926	19980817
EP 1017684	B1	20021120	WO 1998-EP5184 W 19980817	19980817
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		EP 1998-946346 19980817	
			DE 1997-19744003A 19970926	19980817

JP 2001518471	T2	20011016	WO 1998-EP5184 W 19980817 JP 2000-513843 19980817 DE 1997-19744003A 19970926 WO 1998-EP5184 W 19980817
AT 228116	E	20021215	AT 1998-946346 19980817 DE 1997-19744003A 19970926 WO 1998-EP5184 W 19980817
PT 1017684	T	20030331	PT 1998-98946346 19980817 DE 1997-19744003A 19970926
ES 2188011	T3	20030616	ES 1998-946346 19980817 DE 1997-19744003A 19970926
US 6083479	A	20000704	US 1998-157959 19980922 DE 1997-19744003A 19970926
NO 2000001556	A	20000523	NO 2000-1556 20000324 DE 1997-19744003A 19970926 WO 1998-EP5184 W 19980817
OS MARPAT 130:275757			
AB	1,4,7,10-Tetraazacyclododecane derivs. and their rare earth complexes as novel compds. suitable as contrasting agents, in particular for infarct and necrosis imaging, are disclosed, as well as processes for preparing the same and pharmaceuticals containing these compds. Thus, sym-diethylenetriaminepentaacetic acid tetra-tert-Bu ester in presence of N-hydroxysuccimide in DMF was treated with dicyclohexylcardodiimide and subsequently with glycine in presence of Et <sub>3</sub> N to give 3,9-bis(N-tert-butoxycarbonylmethyl)-6-[N-(3-aza-2-oxo-4-carboxy)butyl]-3,6,9-triazaundecane-1,11-dicarboxylic acid di-tert-Bu ester (I). I was reacted with 1,4,7,10-tetraazacyclododecane in DMF in presence of 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline to give 1,4,7-tris{3,9-bis(N-tert-butoxycarbonylmethyl)-6-[N-(3-aza-2,5-dioxo)pentan-1,5-diyl]-3,6,9-triazaundecanedicarboxylic di-tert-Bu ester}-1,4,7,10-tetraazacyclododecane which was reacted with hexadecanoic acid in DMF to give 1,4,7-tris{3,9-bis(N-tert-butoxycarbonylmethyl)-6-[N-(3-aza-2,5-dioxo)pentan-1,5-diyl]-3,6,9-triazaundecanedicarboxylic di-tert-Bu ester}-10-[N-n-hexadecanoyl]-1,4,7,10-tetraazacyclododecane (II). II in CF <sub>3</sub> CO <sub>2</sub> H reacted with Gd <sub>2</sub> O <sub>3</sub> in presence of NaOH to give after deprotection the Na salt of the Gd complex of the deprotected II.		
IT 192636-26-3P 192636-28-5P 222033-44-5P	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (reactant for preparation of rare earth complexes with alkylcarbonyl derivs. of tetraazacyclododecane as MRI contrast agents for myocardial infarction and renal ischemia)		
RN 192636-26-3 CAPLUS			
CN Benzoic acid, 3,5-bis[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)			






RN 192636-28-5 CAPLUS  
 CN Carbamic acid, [1,4,7,10-tetraazacyclododecane-1,4,7-triyltris[carbonyl-5,1,3-benzenetriylbis[imino(2-oxo-2,1-ethanediyl)]]]hexakis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B






RN 222033-44-5 CAPLUS  
 CN Carbamic acid, [[10-(1-oxotetradecyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyltris[carbonyl-5,1,3-benzenetriylbis[imino(2-oxo-2,1-ethanediyl)]]]hexakis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1998:87706 CAPLUS  
DN 128:154388  
TI Preparation of peptide analogs with growth hormone releasing properties  
IN Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning  
PA Novo Nordisk A/S, Den.; Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning  
SO PCT Int. Appl., 178 pp.  
CODEN: PIXXD2  
DT Patent  
LA English

## FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803473	A1	19980129	WO 1997-DK314	19970717
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU	9734346	A1	19980210	DK 1996-803	A 19960722
				AU 1997-34346	19970717
				DK 1996-803	A 19960722
				WO 1997-DK314	W 19970717
EP	923539	A1	19990623	EP 1997-930368	19970717
EP	923539	B1	20020605		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US	5922770	A	19990713	DK 1996-803	A 19960722
				WO 1997-DK314	W 19970717
				US 1997-896550	19970717
JP	2000515517	T2	20001121	DK 1996-803	A 19960722
				JP 1998-506465	19970717
				DK 1996-803	A 19960722
				WO 1997-DK314	W 19970717
EP	1184370	A2	20020306	EP 2001-123155	19970717
EP	1184370	A3	20020327		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT	218537	E	20020615	DK 1996-803	A 19960722
				EP 1997-930368	A319970717
				AT 1997-930368	19970717
				DK 1996-803	A 19960722
ZA	9706371	A	19980122	WO 1997-DK314	W 19970717
				ZA 1997-6371	19970718
				DK 1996-803	A 19960722
US	6127354	A	20001003	US 1999-270862	19990317
				DK 1996-803	A 19960722
				US 1997-896550	A319970717
US	6274584	B1	20010814	US 2000-619227	20000719
				DK 1996-803	A 19960722
				US 1997-896550	A319970717
				US 1999-270862	A319990317
OS	MARPAT 128:154388				
AB	The present invention relates to novel peptide analogs of general formula I [A = X-A1; X = alkylene chain optionally substituted and/or optionally containing O, S, or C:C double bond; A1 = N-containing heterocycle, (aminoalkyl)phenyl, (aminoalkyl)thienyl; G = H, halo, C1-6 alkyl, aryl, C1-6 alkoxy, CONR39R40, (CH2)pNR39SO2R41, (CH2)pNR39COR40, (CH2)pOR41, (CH2)pO2CR40, CHR39R40, CONR39NR40R42, (CH2)pNR39CSNR40R42, (CH2)pNR39CONR40R42; R39, R40 = independently H, (un)substituted C1-6 alkyl, etc.; R41 = aryl-substituted C1-6 alkyl; R42 = C1-6 alkyl; L1, L2 = independently CR57, N; R57 = H, C1-6 alkyl (un)substituted with OH, halo, C1-6 alkoxy, aryl; D, E = independently H, alkoxy, aryl, heteroaryl; R1 = H, C1-6 alkyl; R2 = H, acyl, C1-6 alkyl; R1R2 may form alkylene bridge; R3, R4 = independently H, (un)substituted C1-6 alkyl; R3R4 = O, S; n, m, p = independently 0-3] pharmaceutical compns. containing them, a method of				

stimulating the release of growth hormone from the pituitary, a method for increasing the rate and extent of growth of animals to increase their milk and wool production, or for the treatment of ailments, and to use of the compds. for the preparation of medicaments. Thus, peptidomimetic II was prepared

by standard reactions from (R)-2-[N-tert-butoxycarbonyl-N-methylamino]-3-(2-naphthyl)propionic acid, N-methyl-N-phenethylamine, and (E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid. II and related peptide analogs were tested for growth hormone release in rat pituitary primary cultures in doses ranging from 10 pM to 100 mM. The prepared compds. were also tested for metabolic stability.


IT 202811-34-5P 202811-35-6P 202811-36-7P  
202811-37-8P 202811-38-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of peptide analogs with growth hormone releasing properties)


RN 202811-34-5 CAPLUS

CN Carbamic acid, [2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 202811-35-6 CAPLUS


CN Carbamic acid, [2-[[2-(methylamino)ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



RN 202811-36-7 CAPLUS

CN Carbamic acid, [(1R)-2-[[2-[2-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202811-37-8 CAPLUS

CN Carbamic acid, [2-[[2-[2-[methyl[2-(methylamino)-3-(2-naphthalenyl)-1-oxopropyl]amino]ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202811-38-9 CAPLUS


CN Carbamic acid, [(3E)-5-[[[(1R)-2-[[2-[2-[[4-((2-methoxyacetyl)amino)butyl]amino)phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methylamino]-1,1-dimethyl-5-oxo-3-pentenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A





RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1997:500179 CAPLUS  
 DN 127:122137  
 TI Nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents  
 IN Schmitt-Willich, Heribert; Platzek, Johannes; Raduechel, Bernd; Weinmann, Hanns joachim; Ebert, Wolfgang; Misselwitz, Bernd; Muehler, Andreas; Frenzel, Thomas  
 PA Schering A.-G., Germany  
 SO Ger. Offen., 51 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19549286	A1	19970626	DE 1995-19549286	19951222
	CA 2241187	AA	19970703	CA 1996-2241187	19961129
	WO 9723245	A1	19970703	DE 1995-19549286A	19951222
	W: AU, BG, BY, CA, CZ, IL, JP, KR, MX, NO, NZ, PL, RU, SK, UA, US, VN RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			WO 1996-EP5315	19961129
AU 9710328	A1	19970717	DE 1995-19549286A	19951222	
AU 726034	B2	20001026	WO 1996-EP5315	W 19961129	
EP 868202	A1	19981007	EP 1996-941055	19961129	
EP 868202	B1	20020828	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI	DE 1995-19549286A 19951222	
JP 2000510880	T2	20000822	WO 1996-EP5315 W 19961129		
			JP 1997-523251	19961129	
			DE 1995-19549286A	19951222	
			WO 1996-EP5315 W 19961129		

AT 222776	E	20020915	AT 1996-941055 19961129 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
RU 2197495	C2	20030127	RU 1998-113782 19961129 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
PT 868202	T	20030131	PT 1996-96941055 19961129 DE 1995-19549286A 19951222
ES 2181924	T3	20030301	ES 1996-941055 19961129 DE 1995-19549286A 19951222
SK 283334	B6	20030603	SK 1998-854 19961129 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
ZA 9610822	A	19970627	ZA 1996-10822 19961220 DE 1995-19549286A 19951222
US 5874061	A	19990223	US 1996-777666 19961220 DE 1995-19549286A 19951222
TW 520377	B	20030211	TW 1996-85115801 19961220 DE 1995-19549286A 19951222
US 6057419	A	20000502	US 1998-77773 19980604 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
BG 63105	B1	20010430	BG 1998-102565 19980619 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
NO 9802903	A	19980622	NO 1998-2903 19980622 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
AU 744292	B2	20020221	AU 2000-55021 20000830
AU 2000055021	A5	20001109	DE 1995-19549286A 19951222

AB Complexes containing (a)  $A[X[Y[Z(WKw)z]y]x]a$  ligands ( $A$  = N-containing cascade polymer core with a branching degree,  $X$ ,  $Y$  = direct bond or repeating unit with branching degree  $x$ ,  $y$ , resp.,  $Z$ ,  $W$  = repeating unit with branching degree  $z$ ,  $w$ , resp.,  $K$  = complex formers,  $a$  = 2-12,  $x$ ,  $y$ ,  $z$ ,  $w$  = 1-4,  $\geq 2$  repeating units being different,  $16 \leq axyzw \leq 64$ , and  $\geq 1$  of  $X$ ,  $Y$ ,  $Z$ ,  $W$  being a 1,4,7,10-tetraazacyclododecane or 1,4,8,11-tetraazacyclotetradecane repeating unit), (b)  $\geq 16$  ions of metals with atom. nos. 20-29, 39, 42, 44, or 57-83, (c) optionally, an cation of (in)organic base, amino acid, or amino amide, and (d) optionally, acylated terminal amino group are manufactured for use as pharmaceuticals and contrast agents in NMR tomog. and radiog. A typical complex was manufactured by reaction of HBr with benzylloxycarbonyl-blocked 36mer cascade polyamine prepared from  $N,N,N',N',N'',N'''$ -hexakis(2-aminoethyl)trimesic acid core and 6 1-[5-(4-nitrophenoxy)-3-oxaglutaryl]-4,7,10-tris( $N,N'$ -dibenzylloxycarbonyllsyl)-1,4,7,10-tetraazacyclododecane, reaction of the resulting 36-mer amine hydrobromide with 1-(3-aza-4-carboxy-2-oxobutyl)-4,7,10-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane, and complexation of the Na salt of the resulting ligand with Gd2O3.

IT 192636-26-3P 192636-27-4P 192636-28-5P


192636-29-6P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(cascade polymer precursor; nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents)


RN 192636-26-3 CAPLUS

CN Benzoic acid, 3,5-bis[[[(phenylmethoxy)carbonyl]amino]acetyl]amino- (9CI) (CA INDEX NAME)



RN 192636-27-4 CAPLUS


CN Carbamic acid, [[5-[[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]-1,3-phenylene]bis[imino(2-oxo-2,1-ethanediyl)]]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)






RN 192636-28-5 CAPLUS

CN Carbamic acid, [1,4,7,10-tetraazacyclododecane-1,4,7-triyltris[carbonyl-5,1,3-benzenetriyl]bis[imino(2-oxo-2,1-ethanediyl)]]hexakis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B






RN 192636-29-6 CAPLUS

CN Acetic acid, [2-oxo-2-[4,7,10-tris[3,5-bis[[[(phenylmethoxy)carbonyl]aminο]acetyl]amino]benzoyl]-1,4,7,10-tetraazacyclododec-1-yl]ethoxy]- (9CI)  
(CA INDEX NAME)

PAGE 1-A





IT 192636-30-9P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(complexing cascade polymer precursor; nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents)


RN 192636-30-9 CAPLUS




CN Acetic acid, [2-oxo-2-[4,7,10-tris[3,5-bis[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]benzoyl]-1,4,7,10-tetraazacyclododec-1-yl]ethoxy]-, polymer with N,N,N',N',N'',N'''-hexakis(2-aminoethyl)-1,3,5-benzenetricarboxamide hydrobromide (9CI) (CA INDEX NAME)

CM 1

CRN 192636-29-6


CMF C93 H96 N16 025





CM 2

CRN 192635-87-3  
CMF C21 H39 N9 O3 . x Br H



• x HBr

IT 192636-31-0DP, gadolinium complexes

RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents)

RN 192636-31-0 CAPLUS


CN Sodium(1+), [tris(1,1-dimethylethyl) 10-[1-methyl-2-[2-(4-nitrophenoxy)-2-oxoethyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate-κN1.κN4.κN7.κN101-. bromide. polymer

diacetate RNI, RNI4, RNI7, RNI8, biamide, polymer with N,N',N'',N''-hexakis(2-aminoethyl)-1,3,5-benzenetricarboxamide hydrobromide and [2-oxo-2-[4,7,10-tris[3,5-bis[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]benzoyl]-1,4,7,10-tetraazacyclododec-1-yl]ethoxy]acetic acid (9CI) (CA INDEX NAME)




CM 1

CRN 192636-29-6  
CMF C93 H96 N16 025

PAGE 1-A




PAGE 1-B



CM 2

CRN 192636-00-3  
CMF C37 H60 N6 Na O11 . Br  
CCI CCS




● Br<sup>-</sup>

CM 3

CRN 192635-87-3

CMF C21 H39 N9 O3 . x Br H



● x HBr

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1995:32622 CAPLUS  
 DN 122:31918  
 TI Structure-activity relationships of double-strand RGD peptides as GPIIb/IIIa receptor antagonists  
 AU Ojima, Iwao; Dong, Qing; Eguchi, Masakatsu; Oh, Young-im; Amann, Clare M.; Coller, Barry S.  
 CS School. Medicine, State University New York, Stony Brook, NY, 11794, USA  
 SO Bioorganic & Medicinal Chemistry Letters (1994), 4(14), 1749-54  
 CODEN: BMCLE8; ISSN: 0960-894X  
 DT Journal  
 LA English  
 AB A series of new double-strand RGD peptides M(CO-Arg-Gly-Asp-Phe-OH)2 [M = (CH<sub>2</sub>)<sub>n</sub>, p-C<sub>6</sub>H<sub>4</sub>, n = 2-4] and (R-Arg-Gly-Asp-Phe-NH)2XZ [R = H, Me(CH<sub>2</sub>)<sub>4</sub>CO, Bz, 4-[HN:C(NH<sub>2</sub>)NH]C<sub>6</sub>H<sub>4</sub>CO-Ser; X = Lys, Orn, cis,cis-3,5-diaminocyclohexanecarbonyl, 3,5-(Gly-NH)2C<sub>6</sub>H<sub>3</sub>CO; Z = NH<sub>2</sub>, Gly-Arg-Gly-Asp-Phe-NH<sub>2</sub>, Arg-Gly-Asp-Phe-OH] were prepared and their inhibitory activities evaluated for platelet aggregation. Substantial


improvement in activity is observed with these novel RGD peptides in comparison with single-strand RGD peptides. The structure-activity relationships of these double-strand RGD peptides are discussed.

IT 159581-70-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation, deblocking, and peptide coupling of, with protected  
arginylglycylaspartic acid peptides)

RN 159581-70-1 CAPLUS

CN Benzoic acid, 3,5-bis[[[[[9H-fluoren-9-ylmethoxy) carbonyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1975:86615 CAPLUS

DN 82:86615  
TI Intramolecular rearrangements in peptide derivatives of anthranilic acid  
AU Noguchi, Junzo; Kawai, Megumi; Hamada, Masato  
CS Fac. Sci., Hokkaido Univ., Sapporo, Japan  
SO Israel Journal of Chemistry (1974), 12(1-2), 87-101  
CODEN: ISJCAT; ISSN: 0021-2148

DT Journal

## LA English


AB The peptidylanthranilic acid ester is stable during peptide coupling. However, the amide bond of peptidylanthranilic acid is catalytically hydrolyzed at pH 7. In this reaction, no decomposition or significant racemization of peptide was observed and the protected peptide was easily obtained. Only glycylanthraniloyl derivs. rearranged into peptide and anthranilic acid in aqueous solution

IT 55301-22-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 55301-22-9 CAPLUS

CN Carbamic acid, [2-oxo-2-[[2-[[2-[[phenylmethoxy]carbonyl]amino]ethyl]amino]carbonyl]phenyl]amino]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



=>